Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Evaxion Biotech Announces One-year Data From The Ongoing Phase 2 Trial With Its Lead Asset EVX-01, Personalized Cancer Vaccine

Author: Benzinga Newsdesk | September 16, 2024 07:03am

11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate
15 out of the 16 patients had a reduction of their tumors (target lesions)
79% of EVX-01's vaccine targets triggered a targeted immune response, which compares very favorably to what is seen with other approaches
A positive correlation was observed between the AI-Immunology™ platform predictions and neoantigen immune response (p=0.00013)
EVX-01 as a novel potential melanoma treatment holds a significant commercial potential for Evaxion

Posted In: EVAX